|Mr. Faheem Hasnain||Co-Founder & Chairman||767.3k||N/A||1958|
|Dr. Sheila K. Gujrathi M.D.||Co-Founder, Pres, CEO & Director||767.3k||N/A||1970|
|Mr. Bryan Giraudo||Chief Financial Officer||532.51k||N/A||1976|
|Mr. Christian Waage||Exec. VP, Gen. Counsel & Sec.||551.3k||N/A||1967|
|Dr. Jakob Dupont||Chief Medical Officer||108.33k||N/A||1965|
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications. It has license agreement with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was founded in 2015 and is headquartered in San Diego, California.
Gossamer Bio, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 9.